PDCD1 and cancer: Interestingly, in the tumor microenvironment, the balance of PD1+ CD8+ Teff and Treg lymphocytes is a putative marker of the clinical response to PD1 blockade more reliable than expression of PDL1 or cancer mutation burden (7).